Author Archives: admin


Stem Cell Clinic > Articles by: admin

Leukemia Therapeutics Industry Growth, Trends And Forecast Till 2023 By Marketresearchfuture.Com – Sports Skylark

By Stem Cell Treatment

Leukemia Therapeutics Research Report: by Type (Chemotherapy, Biological, Targeted, Radiation), by Application (Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia) Global Forecast Till 2023

Leukemia TherapeuticsMarket Scenario:

The clinical condition an in which an increased number of abnormal leucocytes or generally called white blood cells of malignant characteristic is called leukemia. Frequent infections, fever with chills and fatigue are early signs of leukemia. Acute, chronic, lymphocytic, and myelogenous leukemias are classified under leukemia. Cancer statistics center of American Cancer Society estimates 61780 new cases of leukemia in 2019. Treatment for such a malicious disease requires intense therapeutic attention. Therefore, the need for accurate treatment in the rising population of leukemia patients is the major factor impelling the global leukemia therapeutics market growth. The traditional therapies involved in the treatment of leukemia are chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The complex pathology of leukemia demands advancements in medical infrastructure for treatment. Hence, letting the market key players immense opportunity to invest in research and development and bring forth innovation in the leukemia therapy. This generates a lead for clinical researchers to investigate better drug administration methods. Efforts which are being made to deliver more effective leukemia therapies is likely to trigger theleukemia therapeutics industry marketgrowth.

However, on the flip side, the high cost of existing leukemia therapies and investment required for developing new therapies is curbing the expansion of leukemia therapeutics market share.

Global leukemia therapeutics market is expected to grow significantly over the forecast period. It is anticipated that the market held the value of USD 10.7 billion in 2017 and is projected to grow at a CAGR of 5.3% during the assessment period predicts Market Research Future (MRFR).

Browse Sample of the Report @https://www.marketresearchfuture.com/sample_request/7425

Segmentation

The global leukemia therapeutics market has been segmented into type, applications, and region.

Based on applications, leukemia therapeutics market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others. The acute lymphocytic leukemia segment is expected to account for the largest share segment of the market in 2017.

Based on type, leukemia therapeutics market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.

Top Key Players

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.

Europe is expected to hold the second largest position in the global leukemia therapeutics market. The market growth in this region is attributed to increase prevalence of leukemia.

The leukemia therapeutics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.

The Middle East & Africa has the least share of the leukemia therapeutics market.

Browse More Report Details @https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

Link:
Leukemia Therapeutics Industry Growth, Trends And Forecast Till 2023 By Marketresearchfuture.Com - Sports Skylark

Hematopoietic Stem Cell Transplantation (HSCT) Market Industry Analysis, Size, Share, Growth, Trends, and Forecasts Application Growth Potential,…

By Stell Cell Research

The Global Hematopoietic Stem Cell Transplantation (HSCT) Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2020 to 2027). The research presents a complete assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported and industry-validated market data.

The Hematopoietic Stem Cell Transplantation (HSCT) Market report begins with a basic overview of the industry lifecycle, definitions, classifications, applications, and industry chain structure and all these together will help leading players understand the scope of the Market, what characteristics it offers, and how it will fulfill customers requirements.

*The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.

Get Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Hematopoietic Stem Cell Transplantation (HSCT), https://www.coherentmarketinsights.com/insight/request-pdf/1250

The major manufacturers covered in this report: Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx, Cynata Therapeutics, Lonza Group Ltd, Cesca Therapeutics Inc, TiGenix N.V., Escape Therapeutics Inc.,Bluebird Bio, and Cellular Dynamics International.

What Hematopoietic Stem Cell Transplantation (HSCT) Market report offers?

1. Hematopoietic Stem Cell Transplantation (HSCT) Market share assessments for the regional and country-level segments 2. Market share analysis of the top industry players worldwide 3. Hematopoietic Stem Cell Transplantation (HSCT) Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) 4. Strategic recommendations in key business segments based on the market estimations

Geographically, this report is scrutinized into several key Regions, with the generation, consumption, revenue (million USD), and market share and growth rate of Hematopoietic Stem Cell Transplantation (HSCT) market in these regions, from 2013 to 2019, covering North America, Europe, China & Japan and its Share (%) and CAGR for the forecasted period 2020 to 2027.

Hematopoietic Stem Cell Transplantation (HSCT) Market Study considers the following Chapters:

Section 1, represents Definition, Specifications, and Classification of Hematopoietic Stem Cell Transplantation (HSCT), Applications of Hematopoietic Stem Cell Transplantation (HSCT), Market Segment by Regions;

Section 2, to break down the Suppliers, and Raw Material, Hematopoietic Stem Cell Transplantation (HSCT) Manufacturing Process, Industry Chain Structure, Manufacturing Cost Structure;

Section 3, to determine the Hematopoietic Stem Cell Transplantation (HSCT) Manufacturing Plants and Technical Data Analysis of Hematopoietic Stem Cell Transplantation (HSCT), Capacity, and Commercial Production Date, R&D Status, Manufacturing Plants Distribution, Raw Materials Sources Analysis, and Technology Source;

Section 4, to demonstrate the Overall Hematopoietic Stem Cell Transplantation (HSCT) Market Analysis, Sales Analysis (Company Segment), Capacity Analysis (Company Segment), Sales Price Analysis (Company Segment);

Section 5 and 6, to demonstrate the Regional Market Analysis that incorporates North America, Europe, China and Japan, Hematopoietic Stem Cell Transplantation (HSCT) Segment Market Analysis (by Type);

Section 7 and 8, to break down the Hematopoietic Stem Cell Transplantation (HSCT) Segment Market Analysis (by Application) Major Manufacturers Analysis of Hematopoietic Stem Cell Transplantation (HSCT);

Section 9, Hematopoietic Stem Cell Transplantation (HSCT) Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trends by Application; Section 10, Regional Marketing Type Analysis, Supply Chain Analysis, International Trade Type Analysis by Hematopoietic Stem Cell Transplantation (HSCT) Market;

Section 11, to investigate the Consumers Analysis of Global Hematopoietic Stem Cell Transplantation (HSCT) Market;

Section 12,13, 14 and 15, to depict Hematopoietic Stem Cell Transplantation (HSCT) deals channel, wholesalers, brokers, merchants, Conclusion and Research Findings, index and information source.

Have Any Query? Ask Our Industry Expert @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1250

Thus, the major key pillars of the Global Hematopoietic Stem Cell Transplantation (HSCT) Market are also described to understand the possible reasons behind the progress of the market. During the examination of the market, researchers studies about factors of the global market that are boosting the performance of the market. Different enterprises are profiled to get a better insight into various effective strategies carried out by them.

In end, the report also presents a 360-degree overview of the competitive scenario of the global Hematopoietic Stem Cell Transplantation (HSCT) market, thus helping organizations understand the major threat and opportunities that vendors in the market are dealt with and include detailed business profiles of some of the major vendors in the market. Also, the report offers a SWOT analysis of the global market. This report gives a clear picture of the market scenario for a better understanding of the readers.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact us:

Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Email: [emailprotected] United States of America: +1-206-701-6702 United Kingdom: +44-020-8133-4027 Japan: +050-5539-1737 India: +91-848-285-0837

Continue reading here:
Hematopoietic Stem Cell Transplantation (HSCT) Market Industry Analysis, Size, Share, Growth, Trends, and Forecasts Application Growth Potential,...

Choroideremia Treatment Market Share Analysis by Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc – Daily Research Advisor

By Gene Therapy Clinics

Global choroideremia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global choroideremia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Data Bridge Market Researchhas added an exhaustive research study of theGlobal Choroideremia Treatment Marketdetailing every single market driver and intricately analyzing the business vertical. The research report has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The research report presents a complete assessment of the market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data.

Global Choroideremia Treatment Marketis expected to grow at a steady CAGR in the forecast period of 2019-2026.Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth. Global Choroideremia Treatment Market By Treatment Type (Gene Therapy, Surgery), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Ophthalmic Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Forecast to 2026

Download exclusive PDF sample report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-choroideremia-treatment-market

Key Developments in the Market:

Reasons to Purchase this Report

Order a Copy of Global Choroideremia Treatment Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-choroideremia-treatment-market

Some of the major competitors currently working in the global choroideremia treatment market areBiogen, 4D Molecular Therapeutics, Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc, PIXIUM VISION, Retina Implant AG, F. Hoffmann-La Roche Ltd and others.

Market Definition:

Choroideremia is also known as choroidal sclerosis is a rare, degenerative, X-linked inherited retinal disorder characterized by progressive degeneration of the choroid, retinal pigment epithelium (RPE) and retina due to Mutations in the CHM gene. This CHM gene required to produce Rab escort protein-1 (REP-1). The condition gets its name from the distinctive sweet odor of affected infants urine and is also c, a protein that takes part in targeting vesicles (small sacs of substances) into, out of, and within cells.

According to the statistics published by U.S. Department of Health & Human Services, an estimated population of choroideremia is about 1 in 50,000-100,000 people. Presence of refined healthcare infrastructure and emerging new market are the key factors for growth of this market.

Market Drivers

Market Restraints

Segmentation:Global Choroideremia Treatment Market

By Treatment

By Route of Administration

By End Users

By Distribution Channel

ByGeography

Download Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-choroideremia-treatment-market

The rest is here:
Choroideremia Treatment Market Share Analysis by Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc - Daily Research Advisor

Why are scientists trying to manufacture organs in space? – TNW

By Stem Cell Medicine

Gravity can be a real downer when you are trying to grow organs.

Thats why experiments in space are so valuable. They have revealed a new perspective into biological sciences, including insights into making human tissues.

Gravity influences cellular behavior by impacting how protein and genes interact inside the cells, creating tissue that is polarized, a fundamental step for natural organ development. Unfortunately, gravity is against us when we try to reproduce complex three dimensional tissues in the lab for medical transplantation. This is difficult because of the intrinsic limitations of bio-reactors used on Earth.

I am a stem cell biologist and interested on brain health and evolution. My lab studies how the human brain is formed inside the womb and how alterations in this process might have lifelong consequences to human behavior, such as in autism or schizophrenia. Part of that work includes growing brain cells in space.

To build organized tissues in the lab, scientists use scaffolds to provide a surface for cells to attach based on a predetermined rigid shape. For example, an artificial kidney needs a structure, or scaffold, of a certain shape for kidney cells to grow on. Indeed, this strategy helps the tissue to organize in the early stages but creates problems in the long run, such as eventual immune reactions to these synthetic scaffolds or inaccurate structures.

By contrast, in weightless conditions, cells can freely self-organize into their correct three-dimensional structure without the need for a scaffold substrate. By removing gravity from the equation, we researchers might learn new ways of building human tissues, such as cartilage and blood vessels that are scaffold-free, mimicking their natural cellular arrangement in an artificial setting. While this is not exactly what happens in the womb (after all the womb is also subject to gravity), weightless conditions does give us an advantage.

And this is precisely what is happening at the International Space Station.

These experiments help researchers optimize tissue growth for use in basic science, personalized medicine and organ transplantation.

But there are other reasons why we should manufacture organs in space. Long-term space missions create a series of physiological alterations in the body of astronauts. While some of these alterations are reversible with time, others are not, compromising future human spaceflights.

Studying astronauts bodies before and after their mission can reveal what goes wrong on their organs, but provides little insights on the mechanisms responsible for the observed alterations. Thus, growing human tissues in space can complement this type of investigation and reveal ways to counteract it.

Finally, all forms of life that we know about have evolved in the presence of microgravity. Without gravity, our brains might have evolved in a different trajectory, or our livers might not filter liquids as it does on Earth.

By recreating embryonic organ formation in space, we can anticipate how the human body in the womb would develop. There are several research initiatives going on in my lab with human brain organoids at ISS, designed to learn the impact of zero gravity on the developing human brain. These projects will have profound implications for future human colonization (can humans successfully reproduce in space?). These studies will also improve the generation of artificial organs that are used for testing drugs and treatments on Earth. Will better treatments for neurodevelopmental and neurodegenerative conditions that affects millions of people come from research in space?

This article is republished from The ConversationbyAlysson R. Muotri, Professor of Pediatrics and Cellular and Molecular Medicine, University of California San Diegounder a Creative Commons license. Read the original article.

Read next: Tesla just became a top 10 US company, but it's still not in the S&P 500

Do you want to get the sassiest daily tech newsletter every day, in your inbox, for FREE? Of course you do: sign up for Big Spam here.

Read the original here:
Why are scientists trying to manufacture organs in space? - TNW

Biobanks Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2025 – Daily Research Chronicles

By Stem Cell Medicine

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market includeBioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read more:
Biobanks Market Analysis Trends, Growth Opportunities, Size, Type, Dynamic Demand and Drives with Forecast to 2025 - Daily Research Chronicles

Global Stem Cell Therapy Market 2020 Coronavirus (COVID-19) Updated Analysis By Product (Autologous, Allogeneic); By Application (Musculoskeletal…

By Stem Cell Treatment

Global Stem Cell Therapy Market Report Industry Analysis, Market Size, Historical-Current-Future Trends, Competitive Landscape and Forecasts to 2026

The markets growth and development depends on the factors such as the modernization and the current technological advancements. This research study on the Stem Cell Therapy market has considered all these aspects and the information provided is based on the current market trends. TheStem Cell Therapy marketreport includes all the minute and important information about the Stem Cell Therapy market which aids the clients to rethink on their current market strategies and implement new ones as per the market standards. The major data points that are mentioned in the Stem Cell Therapy report includes the growth factors, limitations of the market, future market opportunities, market challenges, and others. All these facts about the market are explained in detail so as to the client understands the market condition easily.

Get FREE Sample PDF of This Research Report::https://www.marketdataanalytics.biz/global-stem-cell-therapy-market-report-2020-industry-analysis-15653.html#request-sample

The major market players that are operating in the Stem Cell Therapy market areOsiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix). The market has been segmented based onAutologous, Allogeneic. The market segmentation is not only restricted toMusculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Othersbut also includes the sub segments which also contributes to the market growth and development. The geographical prominence of the Stem Cell Therapy market is categorized into Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. Again the market data is not restricted to regional presence but every prominent country-wise data is also included for understanding the Stem Cell Therapy market in-depth.

Certain conditions that were considered while making Stem Cell Therapy market data analysis include the current market situation, if any kind of restrictions were imposed by any of the regulatory bodies that would have impacted the market growth or development in any kind, the investments that are being made for the market development, for instance, the research and development activities, among others. This extensive data on the Stem Cell Therapy market will prove constructive for all the existing industry players and the new market entrants to improve their decision-making skills to improve their position in the global Stem Cell Therapy market.

View Detailed Report at Link:https://www.marketdataanalytics.biz/global-stem-cell-therapy-market-report-2020-industry-analysis-15653.html

Significant aspects of the Reports and Main Highlights:

A detailed look at the Stem Cell Therapy Industry Changing business trends in the global Stem Cell Therapy market Detailed market bifurcation analysis at different level such as type, application, end user, Regions / countries Historical and forecast size of the Stem Cell Therapy market in terms of Revenue (USD Million) Recent industry development and market trends Competitive Landscape and player positioning analysis for the Stem Cell Therapy market Key Product Offerings by Major players and business strategies adopted Niche and Potential segments (ex. types, applications, and regions/countries) anticipated to observed promising growth Key challenges faced by operating players in the market space Analysis of major risks associated with the market operations

If Any Inquiry of Stem Cell Therapy Report@https://www.marketdataanalytics.biz/global-stem-cell-therapy-market-report-2020-industry-analysis-15653.html#inquiry-for-buying

See the original post here:
Global Stem Cell Therapy Market 2020 Coronavirus (COVID-19) Updated Analysis By Product (Autologous, Allogeneic); By Application (Musculoskeletal...

Could Joe Maddon Lead The Angels To Cubs-like Success In 2020? – Prospect Insider

By Platelet Rich Plasma Injections

The Los Angeles Angels have been in the doldrums recently four straight losing seasons and just one playoff appearance in the Mike Trout era. Enter Joe Maddon, who guided the Cubs to four postseasons in five years and their first World Series win since Teddy Roosevelt was president. Could Maddon lead the Angels to Cubs-like success in 2020?

How much a manager actually influences a baseball teams win-loss record is a never-ending topic of debate for fans and bloggers. Did the team succeed thanks to their skippers field generalship? On the other hand, was it a talented roster? For me, the answer is its usually a blend of both.

No manager couldve made the hapless Detroit Tigers a winner last year. But a skipper could potentially be a positive or negative difference-maker for teams on the fringe of contention. The issue at hand is whether Maddons new squad has the talent to contend this year.

Certainly, Angels GM Billy Eppler tried his best to give Maddon more to work with than predecessor Brad Ausmus had in 2019. In the offseason, Eppler signed all-star third baseman Anthony Rendon, thanks to owner Arte Moreno opening his checkbook. The fifth-year GM also managed to add several other recognizable veterans pitchers Dylan Bundy, Julio Teheran, and Matt Andriese, plus catcher Jason Castro.

So, did Eppler give Maddon the necessary pieces to make the Angels a viable contender in 2020? Lets walk through the roster the 66-year-old skipper will be working with to determine the answer.

Availability was an ongoing problem for the Angels in 2019. No starter remained in the rotation for the entire season with this years Opening Day starter, Andrew Heaney, leading the staff with 18 starts and 95.1 innings.

Compounding matters, Angel pitchers made just 22 quality starts fewest by a team in any season, including campaigns shortened by work stoppage. The league-average for quality starts last season was 51 with the Astros leading MLB with 89. In fact, six pitchers made more quality starts than the Halos.

Pitchers With More Quality Starts Than Angels in 2019

Before Summer Camp began, the projected rotation included Heaney, Shohei Ohtani, Julio Teheran, Dylan Bundy, and GriffinCanning. With Ohtani coming off Tommy John surgery, the Angels will employ a six-man rotation with a gaggle of pitchers vying for the final spot. Initially in the mix were Matt Andriese, Flix Pea, DillonPeters, plus a trio of youngsters Jaime Barra, Patrick Sandoval, and Jos Suarez. But things have already changed.

As already noted, injuries played a significant role in the Angels rotation woes in 2019. Health issues are once again affecting the staffs readiness for the upcoming season.

Teheran reportedly has COVID-19 with mild symptoms, but may return soon. Still, its unlikely the 29-year-old is ready for the start of the season. Ironically, availability has been the nine-year veterans strength. Since 2013, only four pitchers have made 30-plus starts in every season Teheran, Jose Quintana, Jon Lester, and Mike Leake.

On that note, Suarez is one of several Angels on the 10-day IL for undisclosed reasons. Whether its COVID-related or something else remains unknown. As with Teheran, the delay diminishes the odds of the 22-year-old being ready for Opening Day.

Peters is also on the 10-day IL, but thats not a surprise as with Teheran and Suarez. The 27-year-old entered camp expecting to miss a few weeks with a lingering oblique strain from Spring Training. Last season, Peters ERA and xwOBA ranked in the bottom 10-percent of pitchers facing 250-plus hitters.

A pair of currently healthy pitchers likely to receive scrutiny due to recent arm issues are Heaney and Canning.

Heaney has made 20-plus starts just once in five seasons with Los Angeles when he started 30 contests in 2018. Last year, it was elbow and shoulder issues slowing the southpaw. When available, he was brilliant at times striking out 10-plus hitters in four games. Conversely, the 29-year-old didnt reach the sixth inning in half of his outings.

After encountering elbow issues last August, Canning received a platelet-rich plasma (PRP) injection into the elbow in March. The 24-year-old resumed throwing a month later and reported to camp proclaiming his readiness for the season. Good news for both pitcher and team, although Ohtani and Heaney had PRP injections before eventually undergoing TJ surgery.

On a more positive note, injuries undermined Bundys early career, but hes averaged 30 starts since 2017. His 4.83 ERA during this period isnt appealing, yet the 27-year-olds .320 xwOBA was identical to Jeff Samardzija and Marco Gonzales and slightly better than league-average for starters (.324). This suggests pitching home games in hitter-friendly Camden Yards affected right-handers conventional stats.

The short-term loss of Suarez and Peters from early consideration benefits Andriese, who began his career as a starter with the Rays. However, the 30-year-old was an effective full-time reliever with Arizona in 2019. Perhaps Maddon uses the five-year veteran in a variety of roles.

Pea logged 96.1 innings as a starter and reliever before suffering a torn ACL in his right knee last August. Considering his .308 xwOBA as a reliever was significantly better than as a starter (.370), Maddon could piggyback the 30-year-old behind the games starter early in the season or use him as a swing-man.

Sandoval and Barra, both 23-years-old, scuffled last season. Sandoval was a rookie last year, but Barra made 26 starts with a 3.41 ERA as a freshman in 2018. A return to his rookie form would benefit both Barra and the Halos.

Last years bullpen did a commendable job considering starters rarely delivered quality starts and pitched the fewest total innings in the majors. Considering the potential issues the rotation may be facing this year, expect Maddon to turn to his relief corps early and often.

The main contributors to the bullpen in 2019 were closer Hansel Robles, Ty Buttrey, Cam Bedrosian, and No Ramrez. Robles, Bedrosian, and Ramrez were strong. Buttrey began the season well, but slipped during the second half. All return in 2020.

Heading into camp, the leading relievers are Robles, Buttrey, Bedrosian, Ramrez, Ryan Buchter, Justin Anderson, and Keynan Middleton, whos returning from TJ surgery. Candidates to fill out the bullpen include Kyle Keller, Luke Bard, Taylor Cole, Jos Quijada, Parker Markel, Jacob Rhame, and Hector Yan.

The left-handed throwing Quijada is also on the 10-day IL for undisclosed reasons. Perhaps this doesnt matter as much as it did in the past, but the Venezuelan, along with Buchter and Yan, are the only southpaw relievers on the 40-man roster. Furthermore, Yan hasnt pitched above Class-A level.

Many familiar faces return this year with one significant addition. The longest tenured infielder with the team is Albert Pujols, wholl play either first base or designated hitter depending on Ohtanis availability. The 40-year-olds offensive production has been below league-average since 2016. Is it possible Maddon would consider reducing the future Hall of Famers playing time? Bench options include Matt Thaiss, who also possesses third base experience, and rookie Jared Walsh.

Fun Fact: Jared Walsh made 12 relief appearances and saved one game for Class-AAA Salt Lake in 2019. The left-handed thrower also pitched in five games for the Angels.

David Fletcher and Tommy La Stella should be the main stakeholders at second base. Last year, Fletcher paced the team in games played (154) and doubles (30) with only Trout having a higher AVG and OBP. Adding to his value, the 25-year-old demonstrated positional versatility with 20-plus starts at second base, shortstop, third base, and left field.

La Stella was enjoying a breakout season in 2019 earning his first All-Star selection. Unfortunately, the 30-year-old suffered a fractured tibia in early-July, which sidelined him until late September. La Stella also has third base experience.

After posting career bests in AVG, OBP, and OPS+ in 2018, injuries limited the offense and availability of Andrelton Simmons last season. The 30-year-old former Gold Glove winner will be looking to rebound during an abbreviated walk year.

Holding down the hot corner is Rendon, who the team inked to a seven-year/$245 million contract. Last season, the NL MVP finalist set career highs in doubles, home runs, AVG, OBP, SLG, OPS+, and WAR.

The Angels reportedly attempted to trade Luis Rengifo to the crosstown rival Dodger in exchange for outfielder Joc Pederson in the offseason. Entering camp, the 23-year-old seemed like logical fit as back-up middle-infielder before disappearing to the 10-day IL recently. During his rookie season in 2019, switch-hitter started 90 games at second base and 11 contests at shortstop.

Theres still a chance the Rengifo is ready for Opening Day. If the team were to look elsewhere for an infield reserve, potential candidates include non-roster invitee Arismendy Alcntara plus minor leaguers Jose Rojas, Jahmai Jones, and Elliot Soto.

As with the infield, most of the usual suspects return from 2019 with the notable exception of Kole Calhoun, who signed with Arizona. But theres an outside chance a highly-touted prospect joins a future Hall of Famer in the outfield this year.

Lower leg injuries limited left fielder Justin Upton to just 63 games and his worst offensive production since his rookie season in 2007. Upton slashed a lackluster .215/.309/.416 with 12 home runs in 256 plate appearances. The Angels certainly need a bounce back season from the 32-year-old.

Trout, last years MVP, returns in center field. The New Jersey native slashed .291/.438/.645 with 45 home runs and led the majors in OPS+ for a third consecutive season. Its worth noting the 28-year-old has intimated he may not play this year to mitigate the risk of COVID-19 exposure for his wife and unborn child.

In Uptons absence, Brian Goodwin played a career-high 146 games and delivered personal bests in doubles (29), home runs (17), and OPS+ (109). The 29-year-old will begin the season as the everyday right fielder, although its plausible top prospect Jo Adell makes the team and eventually supplants Goodwin.

Still, Adell wasnt expected to be on the Opening Day roster in March and isnt on the 40-man roster. The loss of the minor league season may delay the 21-year-olds MLB debut until next year.

Michael Hermosillo likely serves as the fourth outfielder. The 25-year-old has limited big-league experience since first debuting in 2018, but he can play anywhere in the outfield. Its reasonable to expect Fletcher to see playing time in the outfield. Former first round pick Taylor Ward may be in the mix for a backup job also.

When hes not pitching, Ohtani will serve as primary designated hitter. Although he couldnt pitch last season, the 26-year-old delivered 43 extra-base hits, including 18 home runs, in 106 games. He also lead the team with 5 triples and 12 stolen bases. As noted earlier, Pujols likely fills the DH role when Ohtani is on the mound or unavailable due to pitching responsibilities.

Free agent addition Jason Castro figures to be the regular catcher with Max Stassi likely spotting Castro. With Minnesota last season, the left-handed hitting Castro platooned with MitchGarver. One area to watch; Castros career .553 OPS against southpaws is much lower than against right-handers (.750). Castro has a reputation as a sound defender and pitch framer.

Stassi is strong defensively, but the right-handed hitter hasnt enjoyed much success at the plate during a 183-game career spanning seven seasons. The teams third catcher is Anthony Bemboom. The left-handed hitting Bemboom, who is solid behind the plate, made his MLB debut last year at age-29.

While the addition of Rendon and Ohtanis return to the mound provides a boost, starting pitcher health once again looms as a potential showstopper. Perhaps the truncated 60-game season diminishes the importance of a deep rotation. If thats the case, Maddon may be able to compensate for his staffs shortcomings by having a quick hook with struggling starters. Thats assuming the bullpen performs as it did in 2019.

Still, the Angels chronic difficulties with starting pitcher availability is tough to overlook. For this reason, I believe the AL West is out of reach, even with Maddon at the helm. Maybe the three-time Manager of the Year can elevate to fringe contender status, but its tough envisioning the team earning a wild card berth in the highly competitive American League.

This disappoints me since Id like to see Trout, baseballs best player, add meaningful October baseball to his already-brimming Hall of Fame rsum.

My Oh My

(Photo of Joe Maddon AP)

In 2014, Luke joined the Prospect Insider team and is now a contributor at HERO Sports also. During baseball season, he can be often found observing the local team at T-Mobile Park.

You can follow Luke on Twitter @luke_arkins

Read the original:
Could Joe Maddon Lead The Angels To Cubs-like Success In 2020? - Prospect Insider

Starter Guide to induced Pluripotent Stem Cells (iPSCs …

By Induced Pluripotent Stem Cells

This post was contributed by Kusumika (Kushi) Mukherjee.

The ultimate goal in the field of regenerative medicine is to replace lost or damaged cells. Here, I will discuss the two major processes by which an adult somatic cell is converted to a different cell type for regeneration and repair and situations where one process is favored over the other.

Cell conversion happens via:

The reversal of a differentiated cell type to an undifferentiated state and then redifferentiation into the cell type of choice in vitro is known as reprogramming [1]. The process can be divided into two stages:

The dedifferentiation stage involves overexpression of four reprogramming factors- OCT4, SOX2, KLF4, and C-MYC - that induce a differentiated somatic cell to revert back to a pluripotent stage (iPSC formation) [2, 3]. The iPSCs then proliferate and redifferentiate to another cell type of choice. The four reprogramming factors can be delivered and expressed in multiple somatic cells via various methods. Some of the more common delivery methodsinclude retrovirus [2], lentivirus [4], adenovirus [5], Sendai virus [6], plasmid electroporation (episomal) [7, 8] and mRNA transfection [9]. Many of the plasmids used for these methods can be found on Addgenes stem cell page. On this page, you can also find a table with a list of methods and the species they were used in. iPSCs have now been generated from many different types of somatic cells. The goal is to use cells that can be easily isolated from donors. Apart from fibroblasts, human keratinocytes from hair pluck, peripheral blood cells, and renal epithelial cells from urine are some of the easily isolated somatic cells that have been reprogrammed to iPSCs successfully [10-12].

The next stage of reprogramming consists of redifferentiation of iPSCs into the cell type of choice. This step is sometimes also referred to as directed differentiation. Specific cell media, supplements, bioactive small molecules, and growth factors are used to control the cell fate of iPSCs and differentiate them into different cell lineages [13]. Over the last decade, many cell types have been successfully differentiated from human iPSCs. Below is a list of some of these cell types[13]:

You can find a variety of plasmids for differentiation here.

Dedifferentiation to an intermediate pluripotent state is not always obligatory in cell conversion processes [35]. Rather than reprogram cells all the way back to their most primitive pluripotent stem cell state, through transdifferentiation adult somatic cells are converted directly into a different cell type, bypassing the lengthy processes of reprogramming. The process was first observed in the regenerating lens of the newt over 100 years ago [36]. While natural transdifferentiation is rare in mammals, an example is observed in the pancreas when excess -cell damage results in the transdifferentiation of glucagon-producing -cells into insulin-producing -like-cells [37, 38].

In 1987, Davis et al. reported one of the earliest examples of transdifferentiation in vitro where treatment of mouse fibroblasts with 5-azacytidine led to their conversion into myoblasts [39]. In 2000, Ferber et al. showed for the first time that mouse liver cells could be transdifferentiated in vivo to pancreatic -like-cells with the expression of pancreatic and duodenal homoeobox gene1 (PDX1) [40]. In recent works, transdifferentiation is usually carried out by expressing transcription factors specific to the lineage of the target cell in the original somatic cells [41]. The in vivo and in vitro methods are similar except that the vectors carrying the transdifferentiation factors are directly injected into the organ of interest for in vivo transdifferentiation. Multiple cell types such as fibroblasts, hepatocytes, and pancreatic exocrine cells have been successfully transdifferentiated into neurons and -cells [40-42].

Both reprogramming and transdifferentiation convert differentiated somatic cells into another cell type. However, these two approaches differ in several ways. Below is a table listing some of critical differences (adapted from Zhou and Melton, 2008, [43]):

Overall, reprogramming is very flexible. It offers unlimited potential to produce all cell types in the body. On the other hand, only few cell types have been currently transdifferentiated successfully, limiting the utility of this process. Moreover, it is much easier to genetically modify cells during the reprogramming process as they are propagated in vitro as part of the process. This opens up a wide range of possibilities in clinical situations. In cases where the objective is to fix a disease-inducing genetic mutation in a patient, trying to transdifferentiate any of the patients cells will not alleviate the problem. The best option then would be to dedifferentiate cells from the patient in vitro then correct the damaged gene in the resulting iPSCs before differentiating the cells into the correct lineage and returning them back to the patient.

In this post, I have detailed the two major processes by which cells are converted to replenish and repair cells that are lost or damaged. Both transdifferentiation and reprogramming give researchers the ability to convert a differentiated cell to a different cell type. While transdifferentiation is suited for switching cell types between similar lineages, reprogramming is more versatile and universal.

Many thanks to our guest blogger, Kusumika (Kushi) Mukherjee.

Kusumika (Kushi) Mukherjee is the Editor ofTrends in Pharmacological Sciences,a Cell Press reviews journal. She joined Cell Press to pursue a career in science communication and publishing after completing her postdoctoral training from Massachusetts General Hospital and Harvard Medical School. Connect with her on LinkedIn @https://www.linkedin.com/in/kmukherjeephd/.

References

1. Hochedlinger, K. and R. Jaenisch, Nuclear reprogramming and pluripotency. Nature, 2006. 441(7097): p. 1061-7. PubMed PMID: 16810240.

2. Takahashi, K., et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007. 131(5): p. 861-72. PubMed PMID:18035408.

3. Takahashi, K. and S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006. 126(4): p. 663-76. PubMed PMID:16904174.

4. Yu, J., et al., Induced pluripotent stem cell lines derived from human somatic cells. Science, 2007. 318(5858): p. 1917-20. PubMed PMID:18029452.

5. Stadtfeld, M., et al., Induced pluripotent stem cells generated without viral integration. Science, 2008. 322(5903): p. 945-9. PubMed PMID:18818365. PubMed Central PMCID:PMC3987909.

6. Ban, H., et al., Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci U S A, 2011. 108(34): p. 14234-9. PubMed PMID:21821793. PubMed Central PMCID:PMC3161531.

7. Yu, J., et al., Human induced pluripotent stem cells free of vector and transgene sequences. Science, 2009. 324(5928): p. 797-801. PubMed PMID:19325077. PubMed Central PMCID:PMC2758053.

8. Okita, K., et al., Generation of mouse induced pluripotent stem cells without viral vectors. Science, 2008. 322(5903): p. 949-53. PubMed PMID:18845712.

9. Warren, L., et al., Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 2010. 7(5): p. 618-30. PubMed PMID:20888316. PubMed Central PMCID:PMC3656821.

10. Aasen, T., et al., Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol, 2008. 26(11): p. 1276-84. PubMed PMID:18931654.

11. Loh, Y.H., et al., Reprogramming of T cells from human peripheral blood. Cell Stem Cell, 2010. 7(1): p. 15-9. PubMed PMID:20621044. PubMed Central PMCID:PMC2913590.

12. Zhou, T., et al., Generation of human induced pluripotent stem cells from urine samples. Nat Protoc, 2012. 7(12): p. 2080-9. PubMed PMID:23138349.

13. Williams, L.A., B.N. Davis-Dusenbery, and K.C. Eggan, SnapShot: directed differentiation of pluripotent stem cells. Cell, 2012. 149(5): p. 1174-1174 e1. PubMed PMID:22632979.

14. Sasaki, K., et al., Robust In Vitro Induction of Human Germ Cell Fate from Pluripotent Stem Cells. Cell Stem Cell, 2015. 17(2): p. 178-94. PubMed PMID:26189426.

15. Si-Tayeb, K., et al., Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology, 2010. 51(1): p. 297-305. PubMed PMID:19998274. PubMed Central PMCID:PMC2946078.

16. Zhang, D., et al., Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res, 2009. 19(4): p. 429-38. PubMed PMID:19255591.

17. Spence, J.R., et al., Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature, 2011. 470(7332): p. 105-9. PubMed PMID:21151107. PubMed Central PMCID:PMC3033971.

18. Huang, S.X., et al., Efficient generation of lung and airway epithelial cells from human pluripotent stem cells. Nat Biotechnol, 2014. 32(1): p. 84-91. PubMed PMID:24291815. PubMed Central PMCID:PMC4101921.

19. Dias, J., et al., Generation of red blood cells from human induced pluripotent stem cells. Stem Cells Dev, 2011. 20(9): p. 1639-47. PubMed PMID:21434814. PubMed Central PMCID:PMC3161101.

20. Chang, C.J., et al., Production of embryonic and fetal-like red blood cells from human induced pluripotent stem cells. PLoS One, 2011. 6(10): p. e25761. PubMed PMID:22022444. PubMed Central PMCID:PMC3192723.

21. Grigoriadis, A.E., et al., Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood, 2010. 115(14): p. 2769-76. PubMed PMID:20065292. PubMed Central PMCID:PMC2854424.

22. Jeon, O.H., et al., Human iPSC-derived osteoblasts and osteoclasts together promote bone regeneration in 3D biomaterials. Sci Rep, 2016. 6: p. 26761. PubMed PMID:20065292. PubMed Central PMCID:PMC2854424.

23. Burridge, P.W., et al., Chemically defined generation of human cardiomyocytes. Nat Methods, 2014. 11(8): p. 855-60. PubMed PMID:24930130. PubMed Central PMCID:PMC4169698.

24. Lian, X., et al., Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A, 2012. 109(27): p. E1848-57. PubMed PMID:22645348. PubMed Central PMCID:PMC3390875.

25. Patsch, C., et al., Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol, 2015. 17(8): p. 994-1003. PubMed PMID:26214132. PubMed Central PMCID:PMC4566857.

26. Maffioletti, S.M., et al., Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells. Nat Protoc, 2015. 10(7): p. 941-58. PubMed PMID:26042384.

27. Nejadnik, H., et al., Improved approach for chondrogenic differentiation of human induced pluripotent stem cells. Stem Cell Rev, 2015. 11(2): p. 242-53. PubMed PMID:25578634. PubMed Central PMCID:PMC4412587.

28. Mohsen-Kanson, T., et al., Differentiation of human induced pluripotent stem cells into brown and white adipocytes: role of Pax3. Stem Cells, 2014. 32(6): p. 1459-67. PubMed PMID:24302443.

29. Kogut, I., D.R. Roop, and G. Bilousova, Differentiation of human induced pluripotent stem cells into a keratinocyte lineage. Methods Mol Biol, 2014. 1195: p. 1-12. PubMed PMID:24510784. PubMed Central PMCID:PMC4096605.

30. Lamba, D.A., et al., Generation, purification and transplantation of photoreceptors derived from human induced pluripotent stem cells. PLoS One, 2010. 5(1): p. e8763. PubMed PMID:20098701.

31. Tang, Z.H., et al., Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells. Stem Cells Transl Med, 2016. 5(5): p. 561-71. PubMed PMID:27013738. PubMed Central PMCID:PMC4835250.

32. Ma, L., Y. Liu, and S.C. Zhang, Directed differentiation of dopamine neurons from human pluripotent stem cells. Methods Mol Biol, 2011. 767: p. 411-8. PubMed PMID:21822892.

33. Shi, Y., P. Kirwan, and F.J. Livesey, Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat Protoc, 2012. 7(10): p. 1836-46. PubMed PMID:22976355.

34. Wang, S., et al., Differentiation of human induced pluripotent stem cells to mature functional Purkinje neurons. Sci Rep, 2015. 5: p. 9232. PubMed PMID:25782665. PubMed Central PMCID:PMC4363833.

35. Eguizabal, C., et al., Dedifferentiation, transdifferentiation, and reprogramming: future directions in regenerative medicine. Semin Reprod Med, 2013. 31(1): p. 82-94. PubMed PMID:23329641.

36. Jopling, C., S. Boue, and J.C. Izpisua Belmonte, Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nat Rev Mol Cell Biol, 2011. 12(2): p. 79-89. PubMed PMID:21252997.

37. Merrell, A.J. and B.Z. Stanger, Adult cell plasticity in vivo: de-differentiation and transdifferentiation are back in style. Nat Rev Mol Cell Biol, 2016. 17(7): p. 413-25. PubMed PMID:26979497.

38. Thorel, F., et al., Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature, 2010. 464(7292): p. 1149-54. PubMed PMID:20364121. PubMed Central PMCID:PMC2877635.

39. Davis, R.L., H. Weintraub, and A.B. Lassar, Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell, 1987. 51(6): p. 987-1000. PubMed PMID:3690668.

40. Ferber, S., et al., Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia. Nat Med, 2000. 6(5): p. 568-72. PubMed PMID:10802714.

41. Vierbuchen, T., et al., Direct conversion of fibroblasts to functional neurons by defined factors. Nature, 2010. 463(7284): p. 1035-41. PubMed PMID:20107439. PubMed Central PMCID:PMC2829121.

42. Zhou, Q., et al., In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature, 2008. 455(7213): p. 627-32. PubMed PMID:18754011.

43. Zhou, Q. and D.A. Melton, Extreme makeover: converting one cell into another. Cell Stem Cell, 2008. 3(4): p. 382-8. PubMed PMID:18940730.

Additional Resources on the Addgene Blog

Resources on Addgene.org

Continue reading here:
Starter Guide to induced Pluripotent Stem Cells (iPSCs ...

Cell Culture Protein Surface Coating Market: In-Depth Analysis Of Industry Grow – GroundAlerts.com

By Induced Pluripotent Stem Cells

The study is titled Global Cell culture protein surface coating Market Research Report, in which extensive research has been undertaken by analysts and a detailed evaluation of the global market has been provided. The report includes an in-depth, extensive study of this market in tandem with vital parameters that are likely to have an effect on the market commercialization matrix.

A highly analytical qualitative as well as quantitative evaluation of the global cell culture protein surface coating market has been covered in this report. The study evaluates the myriad aspects of this industry by taking into consideration its historical and forecast data. In the research report, substantial details about Porters five force model, alongside a SWOT analysis as well as a PESTEL analysis of the market are also provided.

Get sample copy of this research report @ https://www.gminsights.com/request-sample/detail/3856

The cell culture protein surface coating market report coverage is inclusive of various parameters such as the market size, regional growth opportunities, major vendors in the market, drivers and constraints, segmental analysis, as well as the competitive landscape.

The main intent of this report is to list down numerous updates and data with respect to the market and also to note the various growth opportunities that are likely to help the market expand at an appreciable rate. An in-depth synopsis of the cell culture protein surface coating market as well as a well-detailed set of market definitions and overview of the industry have been provided in the report.

The abstract section includes information on the cell culture protein surface coating market dynamics. This is further inclusive of the drivers boosting the market growth, market restraints, trends defining the industry, as well as the many growth opportunities prevailing in the industry. Also, details on the pricing analysis in tandem with the value chain analysis have been provided in the study. Historic figures and estimates with respect to the growth of this market throughout the forecast period have been entailed in the study.

The cell culture protein surface coating market report consists of information related to the projected CAGR of the global industry over the forecast period. Also, the numerous technological developments and innovations that are likely to drive the global market share over the anticipated period are mentioned in the study.

Top Companies

Split by Protein Source, the market has been divided into Animal-derived protein, Human-derived protein, Synthetic protein, Plant-derived protein

Animal-derived protein segment is anticipated to witness vigorous growth during the analysis timeframe. Animal derived protein contains high levels of heme iron, vitamin B-12, and saturated fat as well as higher levels of cholesterol augmenting segmental growth. Moreover, animal protein provides muscle health such as lean mass and strength in the quadriceps that further fosters the segmental growth.

Split by Type of Coating, the cell culture protein surface coating market has been divided into Self-coating, Pre-coating, Microwell plates, Petri dish, Flask, Slides

Self-coating segment will grow substantially during the forecast timeline owing to rising investment in research and development. Several biopharmaceutical and biotechnology companies aims on the production of protein therapeutics, production of monoclonal antibody, induced pluripotent stem cells research, cell-based assays development and cryobanking. Above mentioned factors fosters the overall segmental growth.

The regional segmentation covers

Request for a Customization of this research report @ https://www.gminsights.com/roc/3856

What are the key highlights of this report?

Read the rest here:
Cell Culture Protein Surface Coating Market: In-Depth Analysis Of Industry Grow - GroundAlerts.com

Magnetic Resonance Imaging (MRI) Market Applications, Future Trends, Size Value, Growth Statistics, Sales Projection and COVID-19 Impact Analysis By…

By Gene Therapy Clinics

(MENAFN - iCrowdNewsWire) Jul 13, 2020

Magnetic Resonance Imaging (MRI) Market Size, Growth and Share Analysis By Field Strength (High-Field MRI Systems), Type (Close MRI and Open MRI), Disease Application (Brain and Neurological MRI), Regional Outlook and End-Users Forecast to 2023

Magnetic Resonance Imaging (MRI) Market Overview

The magnetic resonate particles are the radio waves that provides the three-dimensional images of the internal organs and joints in the body. MRI shows you the detailed structure of the organ without any invasive surgery. It also detects the heart, surrounding view of the artery and the troubles related to it. MRI study also involves Brain MRI, individual organ MRI and the extremities. The MRI market works on four demands. The Global Magnetic Resonance Imaging (MRI) Market size is anticipated to reach USD 5 billion at a CAGR of 3.5% by the end of 2023, says Market Research Future (MRFR). MRI is a non-invasive diagnostic technology that produces digital images of the internal body structures. It uses the magnetic resonate atoms to show the pictures of the inner body tissue and organs.

The four applications of magnetic resonance imaging market include the non-invasive procedure in practices, the harmful effects of the radiation-based imaging, rising in the research and development of the life science and the increasing use of magnetic resonance imaging in the drug discovery.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/6194

There are certain other factors also that fuel the growth of the MRI market. The primary factor that is increasing the demand for MRI is the increase in the geriatric population. The increase in the geriatric population leads to the rise of cardiovascular, neurological and ophthalmic disorders which results in the growth of the MRI market. However, certain factors affect the growth of magnetic resonance imaging market such as high cost of the instruments, strict regulatory, insufficient reimbursement policies and the lack of skilled operators.

Magnetic Resonance Imaging (MRI) Market Segmentation

The global magnetic resonance imaging market is segmented into four types.

Based on the magnetic field strength, the magnetic resonance imaging market is divided into four types

Based on the architectural model, the MRI market is of two kinds;

based on its application, the global magnetic resonance imaging market is classified into four types. The segmentation includes

The MRI market is also segmented based on end-users that include

As of now, the medium and the high-field segments are having large scale adoption. Usually, the medium and high-field sections produce better image quality to the end-users that helps in better treatment of the disease. The increasing demand for MRI in the hospitals and clinics is rising with the highest MRI market share. The MRI market is one of the significant markets for investment.

Magnetic Resonance Imaging (MRI) Market Regional Outlook

Magnetic Resonance Imaging Market Competitive Landscape:

The global magnetic resonance imaging (MRI) market is getting boosted by the strategic decisions of several companies like Siemens AG, Hitachi, GE Healthcare, Canon Medical Systems, Toshiba Corporation, Philips, Xingaoyi, Toshiba Corporation, and Aurora Imaging Technologies, Inc. These companies are planning mergers, acquisitions, collaborations, and others to ensure their own stand in the market. Their growing investment in the research and development sector is promoting healthy competition, which could ensure a better growth rate in the coming years.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/magnetic-resonance-imaging-market-6194

Magnetic Resonance Imaging (MRI) Market News

Browse More Healthcare Research Reports at:

Structural Heart Devices Market: Type (Heart Valve Devices, Annuloplasty Rings, Occluders, and Delivery Systems), Indication (Valvular Heart Disease, Cardiomyopathy), Procedure (Replacement Procedures, Repair Procedures)Global Forecast Till 2023

https://www.marketresearchfuture.com/reports/structural-heart-devices-market-6385

mHealth Market Information, By Therapeutics(respiratory, mental and neurological disorders, fitness & lifestyle) By Application(monitoring, diagnosis & treatment, wellness & prevention) - Forecast to 2022

https://www.marketresearchfuture.com/reports/mobile-health-market-1816

Gene Editing Market Research Report, By Methods (Crispr, Talen, Zfn, Antisense Technology And Others), By Applications (Plant Genetic Engineering, Animal Genetic Engineering, Gene Therapy, Microorganisms Genetic Engineering), By End User (Biotechnology, Pharmaceutical, Contract Research Organization) Global Forecast Till 2023

https://www.marketresearchfuture.com/reports/gene-editing-market-707

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

View post:
Magnetic Resonance Imaging (MRI) Market Applications, Future Trends, Size Value, Growth Statistics, Sales Projection and COVID-19 Impact Analysis By...

→←